The Medicines and Healthcare products Regulatory Agency (MHRA) has launched a new study into side effects of GLP-1 medicines ...

A common diabetes drug may be the next big thing for migraine relief. In a clinical study, obese patients with chronic ...

A new study finds that the diabetes drug liraglutide significantly reduced monthly migraine days in patients with obesity and ...

Viking Therapeutics initiates VANQUISH phase 3 obesity clinical programme with GLP-1/GIP agonist VK2735: San Diego Thursday, June 26, 2025, 10:00 Hrs [IST] Viking Therapeutics, In ...

Wegovy will be available in a once-weekly innovative pen device in five dose strengths – 0.25 mg, 0.5 mg, 1 mg, 1.7 mg and a ...

Data show that since the drugs were licensed there have been hundreds of cases of acute and chronic pancreatitis ...

To circumvent this, we have expanded our understanding of the structure activity relationship of ASOs conjugated to Glucagon Like Peptide 1 Receptor (GLP1R) agonist peptide ligands. We demonstrate the ...

The United Kingdom's health regulator is investigating weight loss jabs like Ozempic and Mounjaro after linking it to ...

Wegovy is a GLP-1 receptor agonist that acts on key areas of the brain involved in appetite regulation and food intake thereby reducing hunger, improving satiety and reducing cravings for food, ...

A diabetes medication that lowers brain fluid pressure has cut monthly migraine days by more than half, according to a new ...